Mitsubishi Tanabe Pharma Corporation reported consolidated earnings results for the first quarter ended June 30, 2018. For the period, the company has posted revenue of ¥105,351 million against ¥107,708 million a year ago. Core operating profit was ¥19,304 million against ¥21,986 million a year ago. Operating profit was ¥19,304 million against ¥21,050 million a year ago. PBT was ¥19,741 million against ¥21,998 million a year ago. Profit attributable to company was ¥13,959 million against ¥15,981 million a year ago. Diluted per share was ¥24.89. ROE was 86% against 84.3%.

For the six months ending September 2018, the company expects revenue of ¥210,000 million, core ordinary profit of ¥30,000 million, operating profit of ¥28,500 million, profit before income tax was ¥29,000 million and profit attributable to owners of parent of ¥19,500 million or basic earnings per share of ¥34.77.

For the year ending March 31, 2019, the company expects revenue of ¥435,000 million, core ordinary profit of ¥70,000 million, operating profit of ¥67,000 million, profit before income tax was ¥67,500 million and profit attributable to owners of parent of ¥47,000 million or basic earnings per share of ¥83.81.